No significant differences in overall or progression-free survival were observed by mutational status in either cohort.<h4>Conclusion</h4>In this real-world cohort of actionable mutation-negative NSCLC cases, we did not detect significant prognostic associations for TP53, STK11, and KEAP1 mutations, and their incidence was similar between <i>de novo</i> and recurrent disease. This evidence concerns the gene STK11 and non-small cell lung carcinoma.